163 related articles for article (PubMed ID: 30867272)
21. Refractory epilepsy following natalizumab associated PML.
Abkur TM; Kearney H; Hennessy MJ
Mult Scler Relat Disord; 2018 Feb; 20():1-2. PubMed ID: 29253743
[TBL] [Abstract][Full Text] [Related]
22. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
[TBL] [Abstract][Full Text] [Related]
23. Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.
Grebenciucova E; Pruitt A
Curr Neurol Neurosci Rep; 2017 Sep; 17(11):88. PubMed ID: 28940162
[TBL] [Abstract][Full Text] [Related]
24. Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; Wijburg MT; Hartung HP; Killestein J; Adams O; Wattjes MP
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1092-1094. PubMed ID: 28490505
[No Abstract] [Full Text] [Related]
25. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C; Olsson T; Hartung HP
Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
[TBL] [Abstract][Full Text] [Related]
26. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Landy DC; Hecht EM
Clin Neuropharmacol; 2014; 37(2):45-51. PubMed ID: 24614671
[TBL] [Abstract][Full Text] [Related]
27. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.
D'Amico E; Zanghì A; Leone C; Tumani H; Patti F
Drug Saf; 2016 Dec; 39(12):1163-1174. PubMed ID: 27696299
[TBL] [Abstract][Full Text] [Related]
28. Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis.
Moiola L; Rommer PS; Zettl UK
Curr Opin Neurol; 2020 Jun; 33(3):286-294. PubMed ID: 32374570
[TBL] [Abstract][Full Text] [Related]
29. Smoking is not associated with higher prevalence of JC virus in MS patients.
Auer M; Bsteh G; Hegen H; Di Pauli F; Wurth S; Berger T; Deisenhammer F
Eur J Clin Microbiol Infect Dis; 2018 May; 37(5):907-910. PubMed ID: 29423619
[TBL] [Abstract][Full Text] [Related]
30. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
Krämer J; Tenberge JG; Kleiter I; Gaissmaier W; Ruck T; Heesen C; Meuth SG
PLoS One; 2017; 12(4):e0174858. PubMed ID: 28406921
[TBL] [Abstract][Full Text] [Related]
31. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
Gupta S; Weinstock-Guttman B
Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
[TBL] [Abstract][Full Text] [Related]
32. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
33. [[Natalizumab therapy, 2013].
Karácsony M; Bencsik K; Vécsei L
Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
[TBL] [Abstract][Full Text] [Related]
34. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
35. Opportunistic infections and other risks with newer multiple sclerosis therapies.
Berger JR; Houff S
Ann Neurol; 2009 Apr; 65(4):367-77. PubMed ID: 19399841
[TBL] [Abstract][Full Text] [Related]
36. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.
Chan S; Kingwell E; Oger J; Yoshida E; Tremlett H
Mult Scler; 2011 Mar; 17(3):361-7. PubMed ID: 21148660
[TBL] [Abstract][Full Text] [Related]
37. Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
Bargiela D; Bianchi MT; Westover MB; Chibnik LB; Healy BC; De Jager PL; Xia Z
Neurology; 2017 Feb; 88(7):677-684. PubMed ID: 28087821
[TBL] [Abstract][Full Text] [Related]
38. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.
Heesen C; Kleiter I; Nguyen F; Schäffler N; Kasper J; Köpke S; Gaissmaier W
Mult Scler; 2010 Dec; 16(12):1507-12. PubMed ID: 20826527
[TBL] [Abstract][Full Text] [Related]
39. Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?
Mancinelli CR; Scarpazza C; Santuccio G; De Rossi N; Capra R
Neurol Sci; 2018 May; 39(5):965-966. PubMed ID: 29302813
[No Abstract] [Full Text] [Related]
40. PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
Mowry EM; McArthur JC
Neurology; 2017 Mar; 88(12):1110-1111. PubMed ID: 28228562
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
